First-In-Human Study of EOS884448 in Participants with Advanced Cancers.
IO-002 study is a multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers.
Advanced Cancer
DRUG: EOS884448
Percentage of participants with Adverse Events, From first dose date to 90 days after the last dose (up to 48 weeks)|Percentage of participants who experience a Dose Limiting Toxicity, From first study treatment administration through Day 28|Define the recommended Phase 2 dose (RP2D) of EOS884448 in participants with advanced tumors., up to 48 weeks
Mean and median Area under the curve (AUC) of EOS884448 at each dose level, up to 48 weeks|Mean and median Maximum concentration (Cmax) of EOS884448 at each dose level, up to 48 weeks|Percentage of participants with Objective Response as determined by Investigator according to RECIST v1.1or per other specific response criteria according to their tumor type., From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (approximately 48 weeks)|Percentage of participants with anti-drug antibodies to EOS884448, Recorded at baseline (screening), during the first 4 cycles of treatment (4 months), at end of treatment, and 30 and 90 days post last dose (approximately 48 weeks)
Multicenter, open-label, dose-escalation Phase I/IIa clinical study to evaluate the safety and tolerability, PK, PD, and antitumor activity of EOS884448 in participants with advanced cancers. The study will consist in a dose-escalation phase to determine the MTD, the RP2D, and the safety of EOS884448 in participants with advanced cancers.